Form 4: AbbVie Executive Jeffrey Stewart Reports Stock and Option Awards Vesting

EVP, Chief Commercial Officer of AbbVie, Jeffrey Ryan Stewart, reports the vesting of stock awards and options, significantly increasing his holdings in the company.

Summary

• Jeffrey Ryan Stewart, EVP, Chief Commercial Officer of AbbVie, filed a Form 4 detailing changes in his beneficial ownership of AbbVie stock.
• On February 13, 2025, performance-based stock awards and restricted stock units vested, resulting in the acquisition of 19,111, 7,840, 9,268, and 9,432 shares of AbbVie common stock, respectively.
• These awards were granted between February 2022 and February 2024 and were subject to performance-vesting restrictions based on earnings per share and relative total shareholder return or relative return on equity.
• The performance goals were certified as attained by the Compensation Committee of AbbVie's Board of Directors.
• The shares will be issued to the reporting person on February 28, 2025.
• Stewart also acquired options to purchase 33,854 shares of AbbVie common stock at an exercise price of $192.86, exercisable in annual increments starting February 13, 2026.
• Following these transactions, Stewart directly owns 106,592 shares of AbbVie common stock and indirectly owns 1,338 shares through a spouse's trust.
• He also holds options for 33,854 shares.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices and positive performance metrics, suggesting a moderately positive outlook.

Positives

• The vesting of performance-based awards suggests that AbbVie has met certain performance targets related to earnings per share, relative total shareholder return, and relative return on equity.
• Stewart's increased holdings demonstrate his continued investment in and alignment with the company's success.

Future Outlook

The reporting person will receive the shares on February 28, 2025, and the options become exercisable in annual increments starting February 13, 2026.

Industry Context

Executive compensation through stock awards and options is a common practice in the pharmaceutical industry to align management's interests with those of shareholders and incentivize performance.

Comparison to Industry Standards

• Stock option grants and vesting schedules are standard practice for executive compensation in large pharmaceutical companies like AbbVie.
• Companies like Johnson & Johnson, Pfizer, and Merck also utilize similar equity-based compensation plans to incentivize their executives.
• The specific vesting terms and performance metrics (EPS, TSR, ROE) are tailored to AbbVie's strategic goals, but the overall structure is consistent with industry norms.

Stakeholder Impact

• The vesting of stock awards and options aligns executive interests with shareholder value.
• The achievement of performance goals benefits shareholders through increased company performance.

Next Steps

• The shares will be issued to Jeffrey Ryan Stewart on February 28, 2025.
• The options will become exercisable in annual increments starting February 13, 2026.

Key Dates